Delving into the Latest Updates on Jiangxi Shimei Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Infectious Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	10
Chemical drugs	4

Top 5 Target	Count

ACL x NPC1L1	1
Angiotensin II receptor x calcium channel	1
AT1R x L-type calcium channel	1
PLG(Plasminogen)	1
L-type calcium channel x β1-adrenergic receptor	1

主要研究目的：健康试验参与者空腹状态下，单次口服江西施美药业股份有限公司生产的受试制剂布洛芬混悬液（规格：100 ml:2g）或上海强生制药有限公司生产的参比制剂布洛芬混悬液（商品名：美林®（Motrin®）；规格：100 ml:2g），考察空腹状态下受试制剂与参比制剂在健康试验参与者体内的药代动力学参数，评价两制剂的生物等效性。次要研究目的：考察受试制剂和参比制剂在健康试验参与者中的安全性。

[Translation]

Primary Objective: To investigate the pharmacokinetic parameters of the test formulation ibuprofen suspension (100 ml: 2 g) manufactured by Jiangxi Shimei Pharmaceutical Co., Ltd., or the reference formulation ibuprofen suspension (trade name: Motrin®; 100 ml: 2 g) manufactured by Shanghai Johnson & Johnson Pharmaceutical Co., Ltd., in healthy participants under fasting conditions, and to evaluate the bioequivalence of the two formulations. Secondary Objective: To investigate the safety of the test and reference formulations in healthy participants.

Start Date08 Jul 2026

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

CTR20262208

/ CompletedNot Applicable

JSS-221在中国健康试验参与者中的生物等效性试验

[Translation] JSS-221 Bioequivalence Trial in Chinese Health Trial Participants

主要研究目的健康试验参与者空腹或餐后状态下，单次口服江西施美药业股份有限公司生产的受试制剂JSS-221（规格：10mg/片）或H. Lundbeck A/S生产的参比制剂氢溴酸伏硫西汀片（商品名：心达悦；规格：10mg/片），分别考察空腹或餐后状态下受试制剂与参比制剂在健康试验参与者体内的药代动力学参数，评价两制剂的生物等效性。次要研究目的考察受试制剂和参比制剂在健康试验参与者中的安全性。

[Translation]

Primary Study Objective: To investigate the pharmacokinetic parameters of the test formulation JSS-221 (10 mg/tablet) manufactured by Jiangxi Shimei Pharmaceutical Co., Ltd., or the reference formulation vortioxetine hydrobromide tablets (trade name: Xindayue; 10 mg/tablet) manufactured by H. Lundbeck A/S, in healthy participants under fasting or postprandial conditions, and to evaluate the bioequivalence of the two formulations. Secondary Study Objective: To investigate the safety of the test and reference formulations in healthy participants.

Start Date18 Jun 2026

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

CTR20261133

/ CompletedNot Applicable

多替诺雷片在中国健康成年参与者中的生物等效性研究

[Translation] Bioequivalence study of dotenoradine tablets in healthy adult participants in China

主要研究目的：研究空腹/餐后状态下口服受试制剂与参比制剂在中国健康成年参与者体内的药代动力学特征，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂和参比制剂在中国健康成年参与者中的安全性。

[Translation]

Primary objective: To investigate the pharmacokinetic characteristics of the test formulation and the reference formulation in healthy adult participants in China under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial conditions. Secondary objective: To assess the safety of the test formulation and the reference formulation in healthy adult participants in China.

Start Date24 Apr 2026

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

100 Clinical Results associated with Jiangxi Shimei Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangxi Shimei Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Jiangxi Shimei Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jiangxi Shimei Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

4

IND Application

IND Approval

8

5

Phase 3

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bempedoic acid/Ezetimibe ( ACL x NPC1L1 )	Hypercholesterolemia More	Phase 3
Levamlodipine/Bisoprolol ( L-type calcium channel x β1-adrenergic receptor )	Essential Hypertension More	Phase 3
Valsartan/Levamlodipine ( PLG )	Essential Hypertension More	Phase 3
Levamlodipine/Telmisartan ( AT1R x L-type calcium channel )	Essential Hypertension More	Phase 3
SMF-216 ( ACE x calcium channel )	Essential Hypertension More	Phase 3